Amir Nashat
CIK 1575843 · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FATE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 205
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | 197,661 | $3.99 | $788.7K | $12.00M | 4 | 2026-06-12 |
| Morphic Holding, Inc. (MORF) Delisted | Director | 1,991,731 | $56.99 | $113.51M | -$8.69M | 9 | 2024-06-05 |
| SRRK | Director | 1,689,592 | $50.52 | $85.36M | $7.87M | 13 | 2024-05-13 |
| Metacrine, Inc. (MTCR) Delisted | Director | 178,942 | $0.49 | $88.6K | $2.99M | 3 | 2022-09-06 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 153,833 | $0.00 | $62 | $5.00M | 9 | 2022-06-02 |
| FATE | Director | 11,034 | $1.04 | $11.5K | -$17.96M | 21 | 2019-08-02 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 52,156 | $0.88 | $46.0K | -$1.92M | 8 | 2019-06-18 |
| LIFE | Director | 131,469 | $32.20 | $4.23M | $0 | 6 | 2018-05-17 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 1 | 2015-06-10 |
| Receptos, Inc. (RCPT) Delisted | Director | 770,089 | — | — | -$15.80M | 7 | 2013-12-10 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| CAMP | PP VII See Footnote |
197,661 | 100.0% | 2025-09-11 |
| Total | 197,661 | |||
| MORF | Direct | 145 | 0.0% | 2023-06-30 |
| By Polaris Partners VII, L.P. | 1,860,498 | 93.4% | 2023-06-30 | |
| By Polaris Entrepreneurs' Fund VII, L.P. | 130,153 | 6.5% | 2023-06-30 | |
| By Polaris Management Co. VII L.L.C. | 935 | 0.0% | 2023-06-30 | |
| Total | 1,991,731 | |||
| SRRK | Direct | 38,639 | 2.3% | 2024-05-13 |
| PVPFF VI See Footnote |
1,650,953 | 97.7% | 2024-05-13 | |
| Total | 1,689,592 | |||
| MTCR | Polaris Partners VII, L.P. See footnote |
178,942 | 100.0% | 2020-09-22 |
| Total | 178,942 | |||
| SYRS | Polaris Entrepreneurs' Fund VII, L.P. See Footnote |
153,833 | 100.0% | 2016-07-07 |
| Total | 153,833 | |||
| FATE | PVPE V. PVM V is the general partner of PVPE V. The Reporting Person See Footnote |
11,034 | 100.0% | 2019-08-02 |
| Total | 11,034 | |||
| SELB | Polaris Venture Partners V, L.P. See Footnote |
52,156 | 100.0% | 2019-01-29 |
| Total | 52,156 | |||
| LIFE | Direct | 898 | 0.7% | 2015-05-14 |
| By Polaris Venture Partners V, L.P. | 125,992 | 95.8% | 2015-05-14 | |
| By Polaris Venture Partners Entrepreneurs' Fund V, L.P. | 2,456 | 1.9% | 2015-05-14 | |
| Polaris Venture Partners Special Founders' Fund V, L.P. | 1,260 | 1.0% | 2015-05-14 | |
| By Polaris Venture Partners Founders' Fund V, L.P. | 863 | 0.7% | 2015-05-14 | |
| Total | 131,469 | |||
| RCPT | Polaris Venture Partners VI, L.P. See footnotes |
770,089 | 100.0% | 2013-12-10 |
| Total | 770,089 | |||
| No longer reported | ||||
| Polaris Venture Partners Founders? Fund VI, L.P. See Footnote |
959,694 | — | last 2013-11-22 | |
Recent Filings · Page 2 of 9
82 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-30 | Morphic Holding, Inc. (MORF) Delisted | Other (J) | −99,855 | $0 | EDGAR |
| 2023-06-22 | SRRK | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | Morphic Holding, Inc. (MORF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-09-06 | Metacrine, Inc. (MTCR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | SRRK | Buy (P) | +1,197,992 | $5.87M | EDGAR |
| 2022-06-10 | Morphic Holding, Inc. (MORF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-02 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-27 | SRRK | Grant (A) | — | $0 | EDGAR |
| 2022-04-29 | Morphic Holding, Inc. (MORF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-19 | SRRK | Other (J) | −275,648 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).